MiraLax for a Nine-Month-Old with Hard Stool
Yes, MiraLax (polyethylene glycol 3350) can be safely started in a nine-month-old infant for hard stool, with a typical starting dose of approximately 0.8-1.0 g/kg/day, adjusted to achieve 1-2 soft, painless stools daily.
Evidence-Based Dosing and Safety
The research evidence strongly supports PEG 3350 use in infants under 18 months. A retrospective study of 28 infants younger than 18 months (including 3 infants aged 0-5 months and 9 aged 6-11 months) demonstrated that PEG relieved constipation in 97.6% of patients with a mean effective maintenance dose of 0.78 g/kg/day (range 0.26-1.26 g/kg/day) 1. Another study of 75 children under 2 years showed 85% short-term and 91% long-term success with a mean effective dose of 1.1 g/kg/day initially and 0.8 g/kg/day for maintenance 2.
Practical Implementation
For a nine-month-old infant:
- Starting dose: Mix approximately 0.8-1.0 g/kg/day of PEG 3350 powder in any liquid (breast milk, formula, or water)
- Dose adjustment: Parents should titrate the dose to achieve 1-2 soft, painless stools per day
- Duration: Treatment can be continued safely for months; studies show mean treatment duration of 6.2 months (range 3 weeks to 21 months) 1
- Administration: The powder is tasteless and dissolves completely in any beverage 3
Safety Profile
The safety data in infants is reassuring. Adverse effects are minimal and primarily consist of:
- Transient diarrhea (4 out of 28 infants in one study), which resolved with dose adjustment 1
- Increased gas (1 infant) 1
- No subjects discontinued treatment due to adverse effects 2
- No severe clinical or biochemical adverse events in children as young as 6 months 4
Important Caveats
While the FDA labeling for MiraLax indicates use for "occasional constipation" in adults 3, the pediatric research literature demonstrates both safety and efficacy for functional constipation in infants. The medication has been studied for up to 24 weeks in controlled trials 5 and used clinically for much longer periods 1, 2.
Key monitoring points:
- If diarrhea develops, reduce the dose
- If constipation persists despite adequate dosing (up to 1.26 g/kg/day), consider other causes of constipation
- Continue treatment as long as needed; functional constipation in infants often requires months of therapy
Why PEG 3350 Over Alternatives
PEG 3350 is preferred over other laxatives in this age group because it is non-addictive, has excellent palatability (tasteless), demonstrates superior efficacy and safety compared to alternatives, and has the most robust evidence base for use in infants 1, 2, 6, 7. The 2023 AGA-ACG guidelines recommend PEG for chronic constipation with moderate certainty of evidence 8, though these guidelines focus on adults and older children.